Compare · DXCM vs ZIMV
DXCM vs ZIMV
Side-by-side comparison of DexCom Inc. (DXCM) and ZimVie Inc. (ZIMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and ZIMV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $32.95B.
- DXCM has hit the wire 7 times in the past 4 weeks while ZIMV has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 9 for ZIMV).
- Company
- DexCom Inc.
- ZimVie Inc.
- Price
- -
- -
- Market cap
- $32.95B
- -
- 1M return
- +22.54%
- -
- 1Y return
- +14.49%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports Second Quarter 2026 Financial Results
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
Latest ZIMV
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- SEC Form 15-12G filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by ZimVie Inc.
- Amendment: SEC Form 25-NSE/A filed by ZimVie Inc.
- Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Asar Vinit K
- Officer Kidwell Heather returned 83,674 shares to the company, closing all direct ownership in the company (SEC Form 4)